SPECIAL ARTICLE   Free access

Italian Journal of Dermatology and Venereology 2025 April;160(2):97-108

DOI: 10.23736/S2784-8671.25.08110-1

Copyright © 2025 EDIZIONI MINERVA MEDICA

language: English

Cutaneous T-cell lymphomas: a real-life experience of anticipated use of mogamulizumab in Italy

Marco ARDIGÒ ^{1, 2} ✉, Leonardo FLENGHI ³, Adalberto IBATICI ⁴, Cesare MASSONE ⁵, Pietro QUAGLINO ⁶, Miriam TEOLI ⁷, Chandrakala TOLDO ⁸, Tommasina PERRONE ⁹, Alessandra TUCCI ¹⁰, Stefano CACCAVALE ¹¹, Pier L. ZINZANI ^{12, 13}

¹ Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy; ² Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy; ³ Hematology and Bone Marrow Transplantation Unit, Maria della Misericordia Hospital, Perugia, Italy; ⁴ Hematology and Transplant Unit, IRCCS Ospedale Policlinico San Martino, Genoa, Italy; ⁵ Dermatology Unit, Galliera Hospital, Genoa, Italy; ⁶ Dermatologic Clinic, Department of Medical Sciences University of Turin Medical School, Turin, Italy; ⁷ Porphyria and Rare Diseases Unit, IRCCS San Gallicano Institute, Rome, Italy; ⁸ Section of Hematology and Stem Cell Transplantation, APSS Trento, Trento, Italy; ⁹ Hematology Department with Transplant, AOU Policlinico Bari, Bari, Italy; ¹⁰ Hematology - ASST Spedali Civili, Brescia, Italy; ¹¹ University of Campania Luigi Vanvitelli, Naples, Italy; ¹² Lymphoma and Chronic Lymphoproliferative Syndromes Unit, L. e A. Seràgnoli Institute of Hematology, University of Bologna, Bologna, Italy; ¹³ Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy

Mogamulizumab is a humanized monoclonal antibody with enhanced antibody-dependent cell-mediated cytotoxicity that targets chemokine receptor type. Several clinical trials and real-life experiences confirmed the efficacy and safety profiles of mogamulizumab as second-line therapy and beyond, and the biochemical- and dermatology-specific quality of life and physical functioning, with high treatment satisfaction. Systemic drugs are usually used in patients with resistant or advanced forms of cutaneous T-cell lymphomas (especially mycosis fungoides) or with Sézary Syndrome, while early-stage mycosis fungoides can be managed at least initially with local treatments. The most recent Guidelines confirm this approach, but recommend also an anticipated use (starting from the second line) of new therapeutic agents in advanced skin lymphomas. In this report, we discuss eight cases of patients with mycosis fungoides or Sézary Syndrome successfully managed with an anticipated use of mogamulizumab in real-life clinical practice in Italy.

KEY WORDS: Cutaneous T- cell lymphoma; Mycosis fungoides; Sezary Syndrome; Mogamulizumab